echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Phase II single-arm study to evaluate the efficacy of apatinib combined with oral etoposide in the treatment of treated metastatic breast cancer

    Front Oncol: Phase II single-arm study to evaluate the efficacy of apatinib combined with oral etoposide in the treatment of treated metastatic breast cancer

    • Last Update: 2021-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Breast cancer is the most common malignant tumor in women worldwide and the second leading cause of cancer-related deaths


    Breast cancer is the most common malignant tumor in women worldwide and the second leading cause of cancer-related deaths


    The study included patients with HER2-negative metastatic breast cancer (MBC) who had previously received anthracyclines and taxanes and progressed after at least first-line treatment


    The study included patients with HER2-negative metastatic breast cancer (MBC) who had previously received anthracyclines and taxanes and progressed after at least first-line treatment


    31 eligible patients were included in the safety and efficacy assessment



    Efficacy evaluation

    The median progression-free survival was 6.


    The median progression-free survival was 6.



    PFS

    16 patients (51.


    16 patients (51.


    The study found that the median PFS of patients with hypertension was significantly longer than that of patients without hypertension [7.




    The most common grade 3/4 treatment-related AEs were hypertension (12/31,38.


    In summary, studies have shown that apatinib combined with etoposide capsules is effective and tolerable for patients with metastatic HER2-negative breast cancer


    Original source:

    Hu N, Zhu A, Si Y, et al(2021)A PhaseII, Single-Arm Study of Apatinib and Oral Etoposide in Heavily PreTreated Metastatic Breast Cancer.
    Front.
    Oncol.
    10:565384.
    doi: 10.
    3389/fonc.
    2020.
    565384

    Hu N, Zhu A, Si Y, et al(2021)A PhaseII, Single-Arm Study of Apatinib and Oral Etoposide in Heavily PreTreated Metastatic Breast Cancer.
    Front.
    Oncol.
    10:565384.
    doi: 10.
    3389/fonc.
    2020.
    565384

    here message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.